GDF15 Expression in Metastatic Colorectal Cancer (CRC)
Priya Jayachandran, Joanne Xiu, Shivani Soni, Richard Goldberg, Benjamin A. Weinberg, Emil Lou, Michael Hall, Moh’d Khushman, Davendra Sohal, Hiroyuki Arai, Francesca Battaglin, Wu Zhang, Jingyuan Wang, W. Michael Korn, Joshua Millstein, and Heinz-Josef Lenz
GDF15 expression correlates with increased dMMR/MSI-H and TMB, but not with PDL1 expression.
GDF15 is associated with chromatin remodeling which may warrant therapies targeting histone modification and epigenetics.
GDF15 expression is associated with increase in NK cells but decrease in CD8+ T cells in the TME.
The decrease in CD8+ T cells and PDL1 positivity with rising GDF15 suggests worse outcome and a lack of response to anti-PDL1 therapy.
High GDF15 expressing tumors may benefit from immune treatment strategies.
Understanding GDF15 regulation and expression in metastatic colon cancer may reveal which patients could benefit from developing anti-GDF15 targeted therapies against cancer progression.